ATE553769T1 - Inhibitoren der malt1-proteolytischen aktivität und ihre verwendung - Google Patents

Inhibitoren der malt1-proteolytischen aktivität und ihre verwendung

Info

Publication number
ATE553769T1
ATE553769T1 AT08852880T AT08852880T ATE553769T1 AT E553769 T1 ATE553769 T1 AT E553769T1 AT 08852880 T AT08852880 T AT 08852880T AT 08852880 T AT08852880 T AT 08852880T AT E553769 T1 ATE553769 T1 AT E553769T1
Authority
AT
Austria
Prior art keywords
inhibitors
see seq
malt1 proteolytic
proteolytic activity
relates
Prior art date
Application number
AT08852880T
Other languages
English (en)
Inventor
Rudi Beyaert
Peter Marynen
Thijs Baens
Karen Heyninck
Original Assignee
Vib Vzw
Univ Gent
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE553769(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vib Vzw, Univ Gent, Univ Leuven Kath filed Critical Vib Vzw
Application granted granted Critical
Publication of ATE553769T1 publication Critical patent/ATE553769T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT08852880T 2007-11-21 2008-11-20 Inhibitoren der malt1-proteolytischen aktivität und ihre verwendung ATE553769T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US409707P 2007-11-21 2007-11-21
EP07121200 2007-11-21
PCT/EP2008/065925 WO2009065897A2 (en) 2007-11-21 2008-11-20 Inhibitors of malt1 proteolytic activity and uses thereof

Publications (1)

Publication Number Publication Date
ATE553769T1 true ATE553769T1 (de) 2012-05-15

Family

ID=39186759

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08852880T ATE553769T1 (de) 2007-11-21 2008-11-20 Inhibitoren der malt1-proteolytischen aktivität und ihre verwendung

Country Status (6)

Country Link
US (1) US8309523B2 (de)
EP (1) EP2222326B2 (de)
AT (1) ATE553769T1 (de)
AU (1) AU2008327884B2 (de)
CA (1) CA2705694C (de)
WO (1) WO2009065897A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2590971A4 (de) * 2010-06-17 2014-12-10 Fuzians Biomedicals Inc Als antivirale wirkstoffe geeignete verbindungen, zusammensetzungen daraus und verwendungsverfahren dafür
EP2465928A1 (de) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Behandlung von Th17-vermittelten Krankheiten
JP6209516B2 (ja) 2011-08-18 2017-10-04 ニューホープ，エルエルシー 癌治療に使用するための化合物
WO2013053765A1 (en) 2011-10-11 2013-04-18 Proyecto De Biomedicina Cima, S.L. A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
EP2879670A4 (de) * 2012-08-01 2016-03-02 Musc Found For Res Dev Antibakterielle zusammensetzungen und verfahren
US9651513B2 (en) * 2012-10-14 2017-05-16 Synaptics Incorporated Fingerprint sensor and button combinations and methods of making same
EA201590916A1 (ru) * 2012-11-09 2016-02-29 Корнэлл Юниверсити Низкомолекулярные ингибиторы malt1
JP6545197B2 (ja) * 2014-05-28 2019-07-17 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびｍａｌｔ１阻害剤としてのその使用
EP3374361A1 (de) * 2015-11-13 2018-09-19 Novartis AG Neuartige pyrazolopyrimidinderivate
CN105541806A (zh) * 2015-12-25 2016-05-04 中国药科大学 巴比妥酸类化合物、制备方法及其应用
EP3736277A1 (de) 2016-07-29 2020-11-11 Lupin Limited Substituierte thiazolpyridinverbindungen als malt1-inhibitoren
WO2018020474A1 (en) 2016-07-29 2018-02-01 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
EP3495348A4 (de) 2016-07-29 2020-01-22 Toray Industries, Inc. Guanidinderivat und verwendung davon für medizinische zwecke
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
KR20200105678A (ko) 2017-12-28 2020-09-08 더 제너럴 하스피탈 코포레이션 Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
EP3984993A4 (de) * 2019-06-13 2023-07-19 Shanghai Kechow Pharma, Inc. Verwendung von aminothiolverbindungen als hirnnerven- oder herzschutzmittel
IL294214B2 (en) * 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods of using same
EP4284804A1 (de) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclische verbindungen zur behandlung von krebs, autoimmun- und entzündungserkrankungen
CN116554123A (zh) * 2023-04-27 2023-08-08 山东大学 六种噻唑酰腙类化合物在抗肿瘤药物中的应用
WO2024238824A1 (en) * 2023-05-17 2024-11-21 Legend Biotech Usa Inc. Fusion proteins and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055390A1 (en) * 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
GB0013655D0 (en) * 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
AU2003225668A1 (en) * 2002-03-01 2003-09-16 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
US20040110145A1 (en) * 2002-12-09 2004-06-10 Isis Pharmaceuticals Inc. Modulation of MALT1 expression
US20070203236A1 (en) * 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
US9051595B2 (en) † 2007-06-01 2015-06-09 University Of Lausanne Malt1 specific cleavage in assay and screening method

Also Published As

Publication number Publication date
AU2008327884A1 (en) 2009-05-28
EP2222326B1 (de) 2012-04-18
US20110021548A1 (en) 2011-01-27
EP2222326A2 (de) 2010-09-01
EP2222326B2 (de) 2015-02-25
CA2705694C (en) 2015-02-24
US8309523B2 (en) 2012-11-13
CA2705694A1 (en) 2009-05-28
WO2009065897A2 (en) 2009-05-28
WO2009065897A3 (en) 2010-09-23
AU2008327884B2 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
WO2009065897A3 (en) Inhibitors of malt1 proteolytic activity and uses thereof
WO2007106690A8 (en) Degenerate nucleobase analogs
PA8713501A1 (es) INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
NZ600837A (en) 1,3,4-oxadiazole-2-carboxamide compound
WO2007098270A3 (en) Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same
WO2007125103A3 (en) Benzamide glucokinase activators
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2009029847A8 (en) Compositions and methods of using proislet peptides and analogs thereof
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
WO2008118332A3 (en) Hydrazido-peptides as inhibitors of hcv ns3-protease
JO2741B1 (en) Spiro-cyclic nitroblast as protease inhibitors
EA201000329A1 (ru) Циклические депсипептиды
MX2008012424A (es) Proceso convergente para la sintesis de derivados de taxanos.
EA201001404A1 (ru) Амиды 5-оксо-2,3,4,5-тетрагидробензо[b]оксепин-4-карбоновой кислоты и амиды 2,3-дигидробензо[b]оксепин-4-карбоновой кислоты для лечения и предотвращения диабета 1 и 2 типа
WO2009008913A3 (en) P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
ATE478863T1 (de) Heterotetracyclische verbindungen als tpo- mimetica
WO2007053765A3 (en) Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
WO2008048121A3 (en) Macrocyclic cysteine protease inhibitors and compositions thereof
MX2009009952A (es) Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2, 2-difenilhexanamida.
WO2009040314A3 (de) Neue heteroarylsubstituierte acetonderivate, geeignet zur hemmung der phospholipase a2
WO2009012039A3 (en) Crystalline polymorphs
WO2009009122A3 (en) Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
WO2007011878A3 (en) Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists